Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
7.24
+0.21 (2.99%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Relmada Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -57.39 | -79.98 | -98.79 | -157.04 | -125.75 | |
| Depreciation & Amortization | - | - | - | - | 0 | |
| Loss (Gain) From Sale of Investments | -0.32 | -0.38 | 0.24 | 4.81 | 1.25 | |
| Stock-Based Compensation | 15.87 | 30.19 | 43.81 | 44.19 | 40.49 | |
| Other Operating Activities | - | - | - | -6.35 | - | |
| Change in Accounts Receivable | - | - | 0.51 | -0.51 | - | |
| Change in Accounts Payable | -2.56 | 0.62 | -1.76 | 0.42 | 2.85 | |
| Change in Other Net Operating Assets | -1.39 | -2.21 | 4.32 | 10.68 | -10.71 | |
| Operating Cash Flow | -45.79 | -51.76 | -51.66 | -103.8 | -91.87 | |
| Investment in Securities | -48.14 | 51.56 | 50.45 | 19.73 | -54.12 | |
| Investing Cash Flow | -48.14 | 51.56 | 50.45 | 19.73 | -54.12 | |
| Issuance of Common Stock | 93.64 | 0.25 | - | 44.7 | 187.94 | |
| Other Financing Activities | -0.07 | -0.29 | -0.1 | 0.32 | - | |
| Financing Cash Flow | 93.56 | -0.04 | -0.1 | 45.02 | 187.94 | |
| Net Cash Flow | -0.36 | -0.23 | -1.3 | -39.05 | 41.95 | |
| Free Cash Flow | -45.79 | -51.76 | -51.66 | -103.8 | -91.87 | |
| Free Cash Flow Per Share | -1.16 | -1.72 | -1.72 | -3.50 | -5.23 | |
| Cash Income Tax Paid | 0 | - | - | - | - | |
| Levered Free Cash Flow | -23.21 | -23.85 | -17.91 | -52.34 | -46.02 | |
| Unlevered Free Cash Flow | -23.21 | -23.85 | -17.91 | -52.34 | -46.02 | |
| Change in Working Capital | -3.95 | -1.58 | 3.08 | 10.59 | -7.86 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.